Effect of Early Memantine Administration on Outcome of Participents with Moderate to Severe Traumatic Brain Injury

Studying the effect of memantine on platelet, platelet/lymphocyte ratio (PLR) and C reactive protein (CRP) & serum NSE levels in participents with moderate to severe TBI as well as outcome.

Investigators evaluate prognostic effect of memantine on participents with moderate to severe TBI. also to estimate which of platelet, platelet/lymphocyte ratio (PLR), C reactive protein (CRP) or serum NSE levels will be affected by administration of memantine in participents with moderate to severe TBI as a predictor of outcome.

Inclusion Criteria:

• Moderate to severe closed TBI with initial GCS of 4-12
• Age from 18 to 65 years of both sexes
• Able to tolerate enteral feeding and drug administration within the first 24 hours of TBI.

Exclusion Criteria:

• Open TBI or patients who would need open craniotomy later on.
• Comorbid illnesses, such as diabetes mellitus, ischemic heart disease, acute myocardial infarction within the past 48 hours, acute or chronic renal insufficiency, hepatic diseases, autoimmune abnormalities, history of epileptic fits and known malignancies.

Patients with chest, cardiac, abdominal trauma or any other trauma requiring mechanical ventilation.

Patients with body mass index (BMI) <18.5 or > 34.9 kg/m2.